TITLE

CELL THERAPEUTICS ACQUIRES ZEVLIN FROM BIOGEN IDEC

PUB. DATE
February 2008
SOURCE
Worldwide Biotech;Feb2008, Vol. 20 Issue 2, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Cell Therapeutics Inc. has acquired Zevalin drug from Biogen Idec, giving Cell Therapeutics sole responsibility for marketing, sales and development of the drug in the U.S. The drug will continue to be sold outside the U.S. by Bayer Schering under an agreement between Biogen and Bayer. Zevalin was approved in 2002 to treat patients with relapsed indolent non-Hodgkin's lymphoma. The drug was the first radioimmunotherapy to be approved by the U.S. Food and Drug Administration.
ACCESSION #
28720277

 

Related Articles

  • Lymphoma Update.  // PharmaWatch: Cancer;May2008, Vol. 7 Issue 5, p4 

    The article offers world news briefs related to lymphoma. Bayer Schering Pharma AG has received an optimistic opinion on Zevalin from the European Committee for Medicinal Products for Human Use (CHMP). Cell Therapeutics Inc.'s study reveals that combination therapy of fludarabine and...

  • Cell Therapeutics: pixantrone offers promise in non-Hodgkin's lymphoma.  // PharmaWatch: Cancer;Dec2008, Vol. 7 Issue 12, p6 

    The article focuses on the development of Pixantrone drug from Cell Therapeutics Inc. in the U.S. in 2008. Cell Therapeutics issued information saying that Pixantrone has improved the rates of confirmed and unconfirmed total remissions by 14.3% and the overall response rates by 22.8%. Pixantrone...

  • EPIX, FDA reach agreement on image re-read of Vasovist.  // Medical Device Daily;2/4/2008, Vol. 12 Issue 23, p10 

    The article reports on an agreement reached by EPIX Pharmaceuticals with the U.S. Food and Drug Administration on its proposal for the re-read of images of its novel blood pool magnetic resonance angiographic (MRA) agent, Vasovist. Vasovist is an injectable intravascular contrast agent designed...

  • OncoMed's Wnt Deal Adds $40M Up Front.  // Bioworld Week;6/21/2010, Vol. 18 Issue 25, p5 

    The article reports that Redwood City, California-based OncoMed Pharmaceuticals Inc. secured a 40 million-worth early stage deal with Berlin's Bayer Schering Pharma AG to develop a drug targeting the Wnt signaling pathway.

  • MS pills are making news.  // Inside MS;Feb/Mar2007, Vol. 25 Issue 1, p28 

    The article focuses on the development of several multiple sclerosis (MS) drugs in the U.S. Serono announced that the drug oral cladribine had been designated a fast-track product by the U.S. Food and Drug Administration. New data from an extension phase after an initial six-month phase 2 trial...

  • Genentech and Biogen Idec obtain FDA complete response for leukemia drug.  // PharmaWatch: Biotechnology;Jan2010, Vol. 9 Issue 1, p17 

    The article reports on U.S. Food and Drug Administration's (FDA) issuance of complete application response for Rituxan plus fludarabine and cyclophosphamide drug for leukemia therapy developed by Genentech Inc. and Biogen Idec Inc. It notes that the applications were based on data from two Phase...

  • COMPANY SPOTLIGHT - Biogen Idec.  // PharmaWatch: CNS;Jul2012, Vol. 11 Issue 7, p42 

    The article profiles Biogen Idec Inc. which is a biotechnology company that focuses on the development, manufacturing and marketing of drugs. It says that the U.S. Food and Drug Administration has accepted the Biogen's new drug application (NDA) for the review of BG-12, or dimethyl fumarate. The...

  • Food and Drug Administration: Drug Approval Process Under the Microscope.  // Chemical Market Reporter;3/14/2005, Vol. 267 Issue 11, pFR4 

    This article reports that the U.S. Food and Drug Administrations (FDA's) decision earlier this month to suspend marketing for Biogen Idec Inc.'s Tysabri in the wake of safety concerns again sparked debate over FDA's drug approval process. The Senate hearings this month come at a time when the...

  • FDA Rejects Pixuvri; CTI to Seek Compassionate Use.  // Bioworld Week;4/19/2010, Vol. 18 Issue 16, p2 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to reject the Pixuvri, pixantrone, an application for refractory aggressive non-Hodgkin's lymphoma (NHL), developed by Cell Therapeutics Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics